Compounds > (S)-Mephenytoin
Page last updated: 2024-11-07

(S)-Mephenytoin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID107921
CHEMBL ID1743264
CHEBI ID179062
SCHEMBL ID21768

Synonyms (45)

Synonym
CHEBI:179062
70989-04-7
(s)-mephenytoin
(s)-(+)-mephenytoin, solid, >=98% (hplc)
(5s)-5-ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione
(5s)-5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
bdbm21361
mephenytoin, d-
s-mephenytoin
NCGC00160394-01
CHEMBL1743264
NCGC00160394-02
C20130
tox21_111783
dtxcid5026126
dtxsid7046126 ,
cas-70989-04-7
2,4-imidazolidinedione, 5-ethyl-3-methyl-5-phenyl-, (s)-
d9818430mw ,
(+)-s-mephenytoin
mephenytoin, (+)-
unii-d9818430mw
(+)-mesantoin
(s)-(+)-mephenytoin
(s)-5-ethyl-3-methyl-5-phenylhydantoin
(+)-mephenytoin
S10442
d-mephenytoin
2,4-imidazolidinedione, 5-ethyl-3-methyl-5-phenyl-, (5s)-
(+)-5-ethyl-3-methyl-5-phenylhydantoin
mephenytoin, (s)-
SCHEMBL21768
NCGC00165924-04
tox21_111783_1
(s)-5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
mfcd00270025
AKOS030530599
GMHKMTDVRCWUDX-LBPRGKRZSA-N
A13366
Q27276264
A934834
EX-A6720
CS-0102758
HY-B1184A
EN300-10845170

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolidine-2,4-dioneAn imidazolidinone with oxo groups at position 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.00240.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency13.33320.000714.592883.7951AID1259369; AID1259392
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.51030.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 2B7Homo sapiens (human)IC50 (µMol)300.00000.10002.50004.9000AID1802994
UDP-glucuronosyltransferase 1-6Homo sapiens (human)IC50 (µMol)300.00004.90004.90004.9000AID1802994
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)IC50 (µMol)300.00000.30003.25807.3000AID1802994
UDP-glucuronosyltransferase 1A4Homo sapiens (human)IC50 (µMol)300.00004.72004.81004.9000AID1802994
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)IC50 (µMol)300.00004.90004.90004.9000AID1802994
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2C19Homo sapiens (human)Km43.80831.70005.38338.7500AID1220711; AID1220712; AID1220713; AID1220714; AID1220715; AID1220716; AID1220717; AID1220718; AID1220719; AID1220720; AID1220721; AID1220722; AID1220723; AID1220724; AID1220725; AID1220726; AID1220727; AID1220728
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
lipid metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
androgen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 2B7Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1-6Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1-6Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
lipid metabolic processUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
retinoic acid bindingUDP-glucuronosyltransferase 2B7Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 2B7Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1-6Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
UDP-glycosyltransferase activityUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1-6Homo sapiens (human)
intracellular membrane-bounded organelleUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (132)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1220603Activity of human recombinant CYP2C19.1A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220747Activity of human recombinant CYP2C19.15 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220622Activity of human recombinant CYP2C19.9 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220618Activity of human recombinant CYP2C19.1B mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220619Activity of human recombinant CYP2C19.5B mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220711Activity of human recombinant CYP2C19.1A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220660Activity of human recombinant CYP2C19.18 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220620Activity of human recombinant CYP2C19.6 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220729Activity of human recombinant CYP2C19.1A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220712Activity of human recombinant CYP2C19.1B mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220744Activity of human recombinant CYP2C19.11 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220719Activity of human recombinant CYP2C19.16 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220699Activity of human recombinant CYP2C19.1B mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220717Activity of human recombinant CYP2C19.14 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220714Activity of human recombinant CYP2C19.10 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220724Activity of human recombinant CYP2C19 D360N mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220627Activity of human recombinant CYP2C19.15 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220700Activity of human recombinant CYP2C19.9 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220721Activity of human recombinant CYP2C19.19 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220666Activity of human recombinant CYP2C19 F168L mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220564Activity of human recombinant CYP2C19 A161P mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220749Activity of human recombinant CYP2C19.18 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220664Activity of human recombinant CYP2C19 D360N mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220567Activity of human recombinant CYP2C19 F168L mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220728Activity of human recombinant CYP2C19 W212C mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220569Activity of human recombinant CYP2C19.16 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220575Activity of human recombinant CYP2C19 M74T mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220661Activity of human recombinant CYP2C19.19 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220563Activity of human recombinant CYP2C19 E92D mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220713Activity of human recombinant CYP2C19.9 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220624Activity of human recombinant CYP2C19.11 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220615Activity of human recombinant CYP2C19.15 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220571Activity of human recombinant CYP2C19.19 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220611Activity of human recombinant CYP2C19.10 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220697Activity of human recombinant CYP2C19 W212C mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220748Activity of human recombinant CYP2C19.16 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220703Activity of human recombinant CYP2C19.13 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220745Activity of human recombinant CYP2C19.13 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220604Activity of human recombinant CYP2C19 E122A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220610Activity of human recombinant CYP2C19.9 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220617Activity of human recombinant CYP2C19.1A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220572Activity of human recombinant CYP2C19 E92D mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220704Activity of human recombinant CYP2C19.14 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220668Activity of human recombinant CYP2C19 W212C mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220742Activity of human recombinant CYP2C19.9 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220623Activity of human recombinant CYP2C19.10 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220725Activity of human recombinant CYP2C19 M74T mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220658Activity of human recombinant CYP2C19.15 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220663Activity of human recombinant CYP2C19 A161P mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220667Activity of human recombinant CYP2C19 E122A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220695Activity of human recombinant CYP2C19 F168L mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220573Activity of human recombinant CYP2C19 A161P mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220605Activity of human recombinant CYP2C19 W212C mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220718Activity of human recombinant CYP2C19.15 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220694Activity of human recombinant CYP2C19 M74T mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220609Activity of human recombinant CYP2C19.8 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220616Activity of human recombinant CYP2C19.16 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220621Activity of human recombinant CYP2C19.8 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220701Activity of human recombinant CYP2C19.10 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220606Activity of human recombinant CYP2C19.1B mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220746Activity of human recombinant CYP2C19.14 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220665Activity of human recombinant CYP2C19 M74T mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220751Activity of human recombinant CYP2C19 E92D mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220568Activity of human recombinant CYP2C19 E122A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220693Activity of human recombinant CYP2C19 D360N mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220576Activity of human recombinant CYP2C19 F168L mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220659Activity of human recombinant CYP2C19.16 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220561Activity of human recombinant CYP2C19.18 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID679599TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM, S-mephenytoin: 100 uM) in Caco-2 cells1999Pharmaceutical research, Mar, Volume: 16, Issue:3
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
AID1220722Activity of human recombinant CYP2C19 E92D mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220565Activity of human recombinant CYP2C19 D360N mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220715Activity of human recombinant CYP2C19.11 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220577Activity of human recombinant CYP2C19 W212C mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220574Activity of human recombinant CYP2C19 D360N mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220608Activity of human recombinant CYP2C19.6 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220626Activity of human recombinant CYP2C19.14 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220723Activity of human recombinant CYP2C19 A161P mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220702Activity of human recombinant CYP2C19.11 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220750Activity of human recombinant CYP2C19.19 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220613Activity of human recombinant CYP2C19.13 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220752Activity of human recombinant CYP2C19 A161P mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220614Activity of human recombinant CYP2C19.14 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220698Activity of human recombinant CYP2C19.1A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220730Activity of human recombinant CYP2C19.1B mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220566Activity of human recombinant CYP2C19 M74T mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220726Activity of human recombinant CYP2C19 F168L mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220562Activity of human recombinant CYP2C19.19 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220696Activity of human recombinant CYP2C19 E122A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220607Activity of human recombinant CYP2C19.5B mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220662Activity of human recombinant CYP2C19 E92D mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as intrinisic clearance for S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220743Activity of human recombinant CYP2C19.10 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220612Activity of human recombinant CYP2C19.11 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 200 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220720Activity of human recombinant CYP2C19.18 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220570Activity of human recombinant CYP2C19.18 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220727Activity of human recombinant CYP2C19 E122A mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220716Activity of human recombinant CYP2C19.13 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1220625Activity of human recombinant CYP2C19.13 mutant expressed in Saccharomyces cerevisiae BJ5457 assessed as S-mephenytoin 4'-hydroxylation per pmol protein at 25 uM after 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1802994UDP-glucuronosyltransferase Activity Assay from Article 10.3109/14756366.2010.518965: \\The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.\\2011Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 26, Issue:3
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's0 (0.00)29.6817
2010's6 (46.15)24.3611
2020's6 (46.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.40 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
coumarin
2H-chromen-2-one: coumarin derivative		2.0610coumarinsfluorescent dye;
human metabolite;
plant metabolite
bupropion
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.		2.0610aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		2101-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
caffeine
[no description available]		210purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
chlorzoxazone
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.		2.43201,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
debrisoquin
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.		210carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		2.0610amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
furafylline
[no description available]		2.0610oxopurine
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		2.4320imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		210C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		2.4720aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
phenacetin
Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione		2.0610acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
sulfaphenazole
Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.		2.0610primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
terfenadine
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.		210diarylmethane
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		2.0610N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
chlormethiazole
Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.		2.0610thiazoles
alpha-naphthoflavone
alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).		2.0610extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		210cyclic ketone;
erythromycin
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0610taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		210delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
oleandomycin
[no description available]		2.0610oleandomycins
1-hydroxymethylmidazolam
1-hydroxymethylmidazolam: metabolite of midazolam. 1-hydroxymidazolam : An imidazobenzodiazepine that is midazolam in which one of the hydrogens of the methyl group is substituted by a hydroxy group. It is the major metabolite of the anesthetic, midazolam.		210aromatic primary alcohol;
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		drug metabolite;
human blood serum metabolite;
human urinary metabolite
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		2.0610cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
tamoxifen
[no description available]		210stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		2.0610homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
6 beta-hydroxycortisol
6 beta-hydroxycortisol: RN given refers to the (6beta,11beta)-isomer; see also record for 6 alpha-hydrocortisol. 6beta-hydroxycortisol : A C21-steroid that is cortisol bearing an additional hydroxy substituent at the 6beta-position. In humans, it is produced as a metabolite of cortisol by cytochrome p450-3A4 (CYP3A4, an important enzyme involved in the metabolism of a variety of exogenous and endogenous compounds) and can be used to detect moderate and potent CYP3A4 inhibition in vivo.		21011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
6beta-hydroxy steroid;
C21-steroid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mammalian metabolite;
probe
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510